Evidence map›Paper›PMID 22528757›Full record

Trial reportChinese journal of integrative medicine2015

A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis.

Mansoor Rastegarpanah, Reza Malekzadeh, Homayoun Vahedi, Maryam Mohammadi, Elham Elahi, Meghedi Chaharmahali, Tahereh Safarnavadeh, Mohammad Abdollahi

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04513015 (Markers of Oxidative Stress in Inflammatory Bowel Disease in Children and Adults), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04513015 naactive not recruitingnot on this mapstarted 2019, after this paper: background citation

Markers of Oxidative Stress in Inflammatory Bowel Disease in Children and Adults: Risk Factors and Implications for a Dietetic Approach

TypeinterventionalSponsorUniversità Politecnica delle MarcheRan2019 to 2024Enrolled155ConditionsInflammatory Bowel DiseasesArmsAntioxidant diet, Normal dietetic scheme
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Dietary supplements for intestinal inflammation.Journal of preventive medicine and hygiene · 2022
    Review
  14. Review
  15. Review
  16. Antioxidant Therapy in Inflammatory Bowel Diseases.Antioxidants (Basel, Switzerland) · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mansoor RastegarpanahDigestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Reza MalekzadehDigestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Homayoun VahediDigestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maryam MohammadiPharmaceutical Branch, Islamic Azad University, Tehran, Iran.
Elham ElahiDigestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Meghedi ChaharmahaliDigestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tahereh SafarnavadehDigestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad AbdollahiFaculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Mohammad@tums.ac.ir.
Tehran University of Medical Sciences · IRIslamic Azad University Pharmaceutical Sciences Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the clinical efficacy of silymarin in ulcerative colitis (UC) patients.

methodsA randomized double blinded placebo-controlled clinical trial was conducted in 80 UC patients whose disease had been documented and were in remission state between September 2009 and October 2010. Patients were assigned to silymarin group (42 cases) and placebo group (38 cases) using a random number table. Either silymarin (140 mg) or placebo (lactose mono-hydrate, corn starch magnesium stearate) tablets were given once daily for 6 months along with their standard therapy. The efficacies were assessed by disease activity index (DAI), frequency difference of the disease flare-up, and paraclinical data.

resultsTen patients (4 in the silymarin group due to nausea and 6 in the placebo group due to disease flare-up and abdominal pain) discontinued the study. An improvement in hemoglobin level (11.8±1.6 g/dL vs. 13.4±1.2 g/dL,P<0.05) and erythrocyte sedimentation rate (23.7±11.5 mm/h vs.10.8±3.2 mm/h,P<0.05) was observed in the silymarin group but not in the placebo group. DAI significantly decreased in the silymarin group and reached from 11.3±3.5 to 10.7±2.8 (P<0.05). Thirty-five out of 38 patients in the silymarin group were in complete remission with no flare-up after 6 months as compared to 21 out of 32 patients in the placebo group (P=0.5000).

conclusionSilymarin as a natural supplement may be used in UC patients to maintain remission.

Indexed as

AdolescentAdultAgedColitis, UlcerativeDouble-Blind MethodFemaleHumansMaleMiddle AgedPilot ProjectsSilymarinSilymarinrandomized controlled trialsilymarinulcerative colitis

Identifiers

PMID22528757
OpenAlexW2161683919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.